Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: A report from the Children's Oncology Group Study A2971

Alan S. Gamis, Todd A. Alonzo, Robert B. Gerbing, Joanne M. Hilden, April D. Sorrell, Mukta Sharma, Thomas W. Loew, Robert J. Arceci, Dorothy Barnard, John Doyle, Gita Massey, John Perentesis, Yaddanapudi Ravindranath, Jeffrey Taub, Franklin O. Smith

Research output: Contribution to journalArticlepeer-review

Abstract

Transient myeloproliferative disorder (TMD), restricted to newborns with trisomy 21, is a megakaryocytic leukemia that although lethal in some is distinguished by its spontaneous resolution. Later development of acute myeloid leukemia (AML) occurs in some. Prospective enrollment (n = 135) elucidated the natural history in Down syndrome (DS) patients diagnosed with TMD via the use of uniform monitoring and intervention guidelines. Prevalent at diagnosis were leukocytosis, peripheral blast exceeding marrow blast percentage, and hepatomegaly. Among those with life-threatening symptoms, most (n = 29/38; 76%) received intervention therapy until symptoms abated and then were monitored similarly. Organomegaly with cardiopulmonary compromise most frequently led to intervention (43%). Death occurred in 21% but only 10% were attributable to TMD (intervention vs observation patients: 13/14 vs 1/15 because of TMD). Among those solely observed, peripheral blasts and all other TMD symptoms cleared at a median of 36 and 49 days from diagnosis, respectively. On the basis of the diagnostic clinical findings of hepatomegaly with or without life-threatening symptoms, 3 groups were identified with differing survival: low risk with neither finding (38%), intermediate risk with hepatomegaly alone (40%), and high risk with both (21%; overall survival: 92% ± 8%, 77% ± 12%, and 51% ± 19%, respectively; P ≤ .001). Among all, AML subsequently occurred in 16% at a median of 441 days (range, 118-1085 days). The trial is registered at http://www.clinicaltrials.gov as NCT00003593.

Original languageEnglish (US)
Pages (from-to)6752-6759
Number of pages8
JournalBlood
Volume118
Issue number26
DOIs
StatePublished - Dec 22 2011

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint Dive into the research topics of 'Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: A report from the Children's Oncology Group Study A2971'. Together they form a unique fingerprint.

Cite this